文献速递血管炎

美国2007-2022年系统性血管炎患者妊娠结局:基于行政理赔数据的研究

Pregnancy outcomes in patients with systemic vasculitis in the USA from 2007 to 2022: an administrative claims-based study.
PubMed 文献 · Lancet Rheumatol · 2025-10-17

该研究利用美国Merative MarketScan商业理赔数据库(2007-2022年),识别了568例系统性血管炎患者的729次妊娠和5680例无血管炎产科患者的8243次妊娠。

要点

  • 早产和子痫前期/子痫风险因产次和血管大小而异。

核心结论

  • 血管炎患者妊娠发生早产和子痫前期/子痫的风险高于参照产科人群。
  • 疾病特异性因素和合并症对这些结局的贡献需进一步研究,但发现支持孕前咨询和孕期定期监测的重要性。

研究设计与样本

  • 血管炎按血管大小分类为大血管、中血管、小血管和可变血管。
  • 使用最小调整和倾向评分调整回归模型比较结局。

主要发现

  • 血管炎组分娩中位年龄33岁(IQR 29-36)vs 参照组31岁(IQR 28-35)。
  • 早产和子痫前期/子痫风险均因产次和血管大小而异。

临床怎么用

  • 研究结果支持对血管炎患者进行孕前咨询和孕期定期监测。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic vasculitides are rare, heterogeneous, inflammatory disorders associated with high morbidity and mortality. Recent therapeutic advancements have improved life expectancy and reproductive opportunities for patients with vasculitis, but research on preterm delivery, maternal pregnancy complications, and medication use is limited. We aimed to investigate pregnancy outcomes in patients with systemic vasculitis using administrative claims data. METHODS: In this administrative claims-based study, we identified pregnancies in patients aged 15-44 years at the time of delivery with and without (referent population) systemic vasculitis in the Merative MarketScan Commercial Databases from Jan 1, 2007, to Dec 31, 2022. The database includes de-identified inpatient and outpatient health encounters (of mostly privately insured patients) with employment-sponsored health insurance claims in the USA. For patients with vasculitis, at least two outpatient or one inpatient ICD ninth revision clinical modification or ICD tenth revision clinical modification vasculitis-coded visits occurring before or on the last menstrual period of the index pregnancy were required for inclusion in the study. Systemic vasculitis was categorised by vessel size; large, medium, small, and variable. We established the rate of adverse pregnancy outcomes, including hypertensive disorders of pregnancy, placental disorders, and preterm delivery phenotypes in both groups. We also described pregnancy characteristics, medication use, and complications in patients with systemic vasculitis stratified by parity. Outcomes were compared using minimally adjusted and propensity score-adjusted regression models. People with lived experience of vasculitis were not included in this study. FINDINGS: We included 729 pregnancies in 568 patients with vasculitis. 61 (8·4%) were in pregnancies of patients with large vessel vasculitis, 171 (23·5%) with medium vessel vasculitis, 247 (33·9%) with small vessel vasculitis, and 274 (37·6%) with variable vessel vasculitis. 8243 pregnancies in 5680 obstetric patients without vasculitis were included in the referent population. The median age at delivery was higher in the patients with vasculitis than in those in the referent population (33 years [IQR 29-36] vs 31 years [28-35]). Glucocorticoids were the most common treatment during pregnancy in patients with systemic vasculitis, with 159 (21·8%) receiving other immunosuppressive medications. Preterm delivery (before 37 weeks completed gestation) risk was higher in patients with vasculitis than in the referent population, with increased risk in both the minimally adjusted model (adjusted risk ratio [RR] 1·76 [95% CI 1·33-2·33]) and propensity score-adjusted model (propensity score-adjusted RR 1·52 [1·13-2·03]). Pre-eclampsia or eclampsia also occurred at a higher frequency in the population with systemic vasculitis than in the referent population in both models (minimally adjusted RR 1·91 [1·45-2·52] and propensity score-adjusted RR 1·51 [1·11-2·07]). For both preterm delivery and pre-eclampsia or eclampsia, the risk varied by parity and vessel size. INTERPRETATION: Pregnancies in patients with vasculitis had higher risks of preterm delivery and pre-eclampsia or eclampsia than pregnancies in the referent obstetric population. Although the contribution of disease-specific factors and comorbidities on these outcomes requires further investigation, these findings affirm the importance of pre-conception counselling and regular monitoring during pregnancy. FUNDING: Stanford Maternal Child Health Research Institute; Stanford Institute for Immunity, Transplantation, and Infection; and Stanford Autoimmune and Allergy Supergroup.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Horomanski A, Rector A, Shaw GM, et al. Pregnancy outcomes in patients with systemic vasculitis in the USA from 2007 to 2022: an administrative claims-based study. Lancet Rheumatol. 2025. PMID: 41115440. doi:10.1016/S2665-9913(25)00218-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。